Login to Your Account



Other News To Note


Monday, June 17, 2013

• Inovio Pharmaceuticals Inc., of Blue Bell, Pa., said a preclinical study of its influenza DNA vaccine against the newly emergent virulent H7N9 flu virus showed that the vaccine achieved immune response levels exceeding what are considered protective levels in other common influenza subtypes.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription